Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Budesonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 13/20 | 1.00 |
| ▸ | PGR | P06401 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | IL5 | P05113 | 1/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 1/20 | 1.00 |
| ▸ | AR | P10275 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | MMP9 | P14780 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Budesonide SCHEMBL16139563 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL17168987 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL9763339 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL12440030 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL19635 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL10020756 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL17151422 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL17971368 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL13918824 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 | |
| Budesonide SCHEMBL21570019 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4HIF1ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124613-A1 | Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | US | disclosed |
| EP-1922074-B1 | A COMBINATION OF COMPOUNDS, WHICH CAN BE USED IN THE TREATMENT OF RESPIRATORY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA. | ASTRAZENECA AB (SE) | 2010-02-17 | — | — | EP | disclosed |
| US-20090215732-A1 | COMBINATION OF COMPOUNDS, WHICH CAN BE USED IN THE TREATMENT OF RESPIRATORY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| US-20080207577-A1 | Mixture of a P2X7 (purinergic) receptor antagonist, and a corticosteroid; 1-adamantylalkylamide derivatives with benzyl or pyridyl group; respiratory system disorders, chronic obstructive pulmonary disease; antiasthmatics; formoterol, budesonide; kits | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| EP-0875516-B1 | Process for the preparation of 16,17 acetals of pregnane derivatives with control of the epimeric distribution at the C-22 position | FARMABIOS SPA (IT) | 2005-10-12 | — | — | EP | disclosed |
| EP-0994119-B1 | Stereoselective process for the preparation of the 22R epimer of budesonide | FARMABIOS SPA (IT) | 2004-03-31 | — | — | EP | disclosed |
| EP-0613371-B1 | NEW COMBINATION OF FORMOTEROL AND BUDESONIDE | ASTRAZENECA AB (SE) | 2002-03-06 | — | — | EP | disclosed |
| EP-1101493-A2 | New combination of formoterol and budesonide | AstraZeneca AB (SE) | 2001-05-23 | — | — | EP | disclosed |
| US-6169178-B1 | PREPARATION OF BUDESONIDE AND RELATED PREGNANE DERIVATIVES COMPRISING TREATING WITH ALDEHYDES 16,17-DIOLS, KETALS OR CYCLIC ACETALS, IN PRESENCE OF AQUEOUS HYDROBROMIC ACID OR HYDRIODIC ACID AS CATALYSTS AND SOLVENTS | FARMABIOS S.R.L. (IT) | 2001-01-02 | — | — | US | disclosed |
| WO-2000053188-A1 | NEW COMBINATION OF R,R-FORMOTEROL AND BUDESONIDE IN A PHARMACEUTICAL COMPOSITION USEFUL FOR TREATING RESPIRATORY DISORDERS, SUCH AS ASTHMA, RHINITIS AND COPD | ASTRAZENECA AB (SE) | 2000-09-14 | — | — | WO | disclosed |
| EP-0994119-A1 | Stereoselective process for the preparation of the 22R epimer of budesonide | Farmabios S.r.l. (IT) | 2000-04-19 | — | — | EP | disclosed |
| US-5972919-A | FORMOTEROL FUMARATE DIHYDRATE OR A SOLVATE AND BUDESONIDE TOGETHER OR SIMULTANEOUSLY INHALED IN THE FORM OF DRY POWDER TO TREAT ASTHMA | ASTRA AKTIEBOLAG (SE) | 1999-10-26 | — | — | US | disclosed |
| EP-0875516-A2 | Process for the preparation of 16,17 acetals of pregnane derivatives with control of the epimeric distribution at the C-22 position | Farmabios S.r.l. (IT) | 1998-11-04 | — | — | EP | disclosed |
| US-5674860-A | ADMINISTERING MEASURED AMOUNTS OF FORMOTEROL(OR ITS SALTS OR SOLVATES) AND BUDESONIDE BY INHALATION | ASTRA AKTIEBOLAG (SE) | 1997-10-07 | — | — | US | disclosed |
| WO-1997001337-A1 | THE COMBINATION OF TOPICAL NASAL ANTIHISTAMINES AND TOPICAL NASAL STEROIDS | MCNEIL-PPC, INC. (US) | 1997-01-16 | — | — | WO | disclosed |
| WO-1997001341-A1 | THE COMBINATION OF TOPICAL NASAL MAST CELL STABILIZERS AND TOPICAL NASAL STEROIDS | MCNEIL-PPC, INC. (US) | 1997-01-16 | — | — | WO | disclosed |
| EP-0613371-A1 | NEW COMBINATION OF FORMOTEROL AND BUDESONIDE | Astra Aktiebolag (SE) | 1994-09-07 | — | — | EP | disclosed |
| WO-1993011773-A1 | NEW COMBINATION OF FORMOTEROL AND BUDESONIDE | AKTIEBOLAGET ASTRA (SE) | 1993-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215732-A1 | COMBINATION OF COMPOUNDS, WHICH CAN BE USED IN THE TREATMENT OF RESPIRATORY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | NR3C1, NR3C2, CHRM3 | NR3C1 1/4885PGR 189/4885CYP3A4 219/4885 |
| US-20110124613-A1 | Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | GRK5, ADRB2, GRK2 | NR3C1 5/4885PGR 911/4885CYP3A4 3040/4885 |
| US-20080207577-A1 | Mixture of a P2X7 (purinergic) receptor antagonist, and a corticosteroid; 1-adamantylalkylamide derivatives with benzyl or pyridyl group; respiratory system disorders, chronic obstructive pulmonary disease; antiasthmatics; formoterol, budesonide; kits | P2RY1, P2RX3, P2RX7 | NR3C1 102/4885PGR 472/4885CYP3A4 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.